RxDoctor Payments Data

Ambar Patel, MD

Cardiovascular Disease · Jacksonville, FLNPI 1366649758

Payments from drug & device makers

$298,180in general payments, 2019–2025

Across 140 payments — averaging $2129.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • American Regent$290K
  • AstraZeneca$3K
  • Novartis$2K
  • Abbott$1K
  • Edwards Lifesciences$928
  • Boston Scientific$593
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$68916%
  • Food & beverage$3,64784%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$298,180 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$212,400
Medicare patients
1,538
Services billed
3,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan502$565,347
EliquisApixaban274$264,426
Repatha SureclickEvolocumab269$192,467
JardianceEmpagliflozin169$187,249
XareltoRivaroxaban50$36,016
FarxigaDapagliflozin Propanediol30$25,886
BrilintaTicagrelor18$18,853
Repatha SyringeEvolocumab23$15,992
Praluent PenAlirocumab14$10,779
CorlanorIvabradine Hcl14$9,769
Metoprolol Succinate320$3,932
Atorvastatin Calcium337$3,420
Ranolazine ErRanolazine41$3,265
Carvedilol352$3,059
ClopidogrelClopidogrel Bisulfate195$2,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$1,699$565,347502 claims
Boehringer IngelheimJardiance$57$187,249169 claims
AstraZenecaFarxiga, Brilinta$2,893$44,73948 claims
Johnson & JohnsonXarelto$12$36,01650 claims
AmgenCorlanor$168$9,76914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →